Document is current
Any future updates will be listed below
-
Authors
,
Vollesen, Anne Luise
Benemei, Silvia
Cortese, Francesca
Labastida-Ramírez, Alejandro
Marchese, Francesca
Pellesi, Lanfranco
Romoli, Michele
Ashina, Messoud
Lampl, Christian http://orcid.org/0000-0003-4340-3486
- License Information
-
More Information
Article History
Received: 14 June 2018
Accepted: 20 August 2018
First Online: 21 September 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Prof Messoud Ashina is a consultant or scientific advisor for Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva, primary investigator for Amgen 20,120,178 (Phase 2), 20,120,295 (Phase 2), 20,130,255 (OLE), 20,120,297 (Phase 3) and GM-11 gamma- Core-R trials, and reports grants from Lundbeck Foundation (R155–2014-171), Research Foundation of the Capital Region of Copenhagen, Danish Council for Independent Research, Medical Sciences and Novo Nordisk Foundation (NNF11OC101433). Prof Christian Lampl is a consultant or scientific advisor for Novartis and Teva. Other authors have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
